FRONTEO signs partnership with CMIC for clinical trials of AI medical devices

2021.05.19 Press release

--To the press -

FRONTEO signs partnership with CMIC for clinical trials of AI medical devices

Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is CMIC Co., Ltd. (Headquarters: Minato-ku, Tokyo, President and CEO: Toru Fujieda, hereinafter Simic) and AI We are pleased to announce that we have entered into a partnership aimed at speeding up and streamlining clinical trials of medical devices.


 As Japan's first CRO (Drug Development Support Organization), CMIC provides business support for domestic clinical trials and international joint clinical trials, from the formulation of development strategies to the implementation of clinical trials.We provide a variety of high-quality services in the development of medical devices and pharmaceuticals, and in recent years, we have been actively working on risk-based monitoring, virtual clinical trials, and utilization of real-world data. In addition, we also support the development of systems in the central nervous system area and the development of AI medical devices.


 Currently, FRONTEO is developing multiple medical AIs, including a mental illness diagnosis support AI system, starting with the "conversational dementia diagnosis support AI system." The reality is that there are still few examples of the development of AI medical devices in Japan.In concluding this partnership, we will accelerate the development of AI medical devices and improve the probability of success by aggregating the knowledge of both CMIC and FRONTEO, who have development experience in such advanced fields.


 FRONTEO aims to realize a society in which patients can receive the necessary treatment at an early stage without regional disparities by delivering advanced equipment to the medical field as soon as possible.


 The impact of this matter alone on FRONTEO's business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.



FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and OSINT from 8, and created by using AI to "turn text data into knowledge". We contribute to solving various corporate issues such as drug support, dementia diagnosis support, financial, human resources, and sales support. Listed on TSE Mothers on June 2014, 2007. January 6, 26 Obtained a first-class medical device manufacturing and sales license (permit number: 2021B1X13).The capital is 13 thousand yen (as of March 1, 10350).


* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc. Segawa

FAX: 03-5463-6345 Email:


<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

ja 日本語
Machine Translation by Google. : close x